Trump Admin Strikes GLP-1 Drug Deal, Medicare Coverage For Weight Loss To Launch Through CMS Pilot

By Maaisha Osman / November 6, 2025 at 7:32 PM

The Trump administration publicly announced its expected deal with Eli Lilly and Novo Nordisk to lower prices on their blockbuster GLP-1 drugs in exchange for Medicare and Medicaid coverage, with an Eli Lilly spokesperson confirming that Medicare coverage for weight-loss indications will be offered through a CMS pilot program that has yet to be announced.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Trump Admin Strikes GLP-1 Drug Deal, Medicare Coverage For Weight Loss To Launch Through CMS Pilot

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.